Biocon Share Price in Focus; Announces US Commercial Launch of Yesafili

Biocon Ltd. has announced the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Regeneron's Eylea 2 mg, in the United States, as per the exchange filings.  

The product is an FDA-approved interchangeable biosimilar, allowing pharmacy-level substitution in accordance with state laws.   

Commercial Launch in the US 

According to the company, Yesafili was commercially launched in the United States on August 3, 2026. The product is a biosimilar aflibercept and is targeted at the international market.  

Interchangeable Biosimilar for Eye Disorders 

Biocon said Yesafili is an FDA-approved interchangeable biosimilar to Eylea 2 mg. The vascular endothelial growth factor (VEGF) inhibitor is indicated for the treatment of ophthalmology conditions, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and macular edema following retinal vein occlusion (RVO).   

Read More: Park Medi World Share Price in Focus After Q1 FY27 Earnings Results: Total Income Up 19.1% YoY! 

Biocon Share Price Performance 

As of August 03, 2026, at 11:10 AM, Biocon share price was trading at ₹426.75 per share, reflecting a surge of 0.25% from the previous trading session. 

Conclusion 

Biocon has commercially launched Yesafili, its biosimilar aflibercept, in the United States. The FDA-approved interchangeable biosimilar expands the company's ophthalmology portfolio and is indicated for the treatment of multiple retinal eye disorders.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.